Food Allergy Peanut
9
4
5
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
0.0%
0 terminated out of 9 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (9)
PK/PD Study of IN-001 Sublingual Spray in Healthy Adults
Intervention to Reduce Early (Peanut) Allergy in Children
Understanding the Immune System's Role in Tree Nut and Peanut Allergies: Key Biomarkers for Diagnosis and Treatment Monitoring and Treatment Targets
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
Expecting Mother's Study of Consumption or Avoidance of Peanut and Egg
EPAP, Interviewstudy
TRANS-FOODS: Preventing Peanut Allergy Through Improved Understanding of the Transcutaneous Sensitisation Route, Novel Food Processing and Skin Care Adaptations
Preventing Anaphylaxis With Acalabrutinib
Novel Treatment for Patients With Peanut Allergy: Intralymphatic Immunotherapy